MYCOF News and Press, New Age Brands From 12/16/21

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers t...

Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing mental health disorders. More and more psychedel...

Opioids are a class of drugs made from the opium poppy plant . These drugs work in the brain to produce various effects, including pain relief. Opioids are usually given as prescription medications to treat moderate to severe pain. However, long-term use of the drugs increases an individual...

The psychedelic renaissance has greatly increased the popularity of psychedelic substances as more research on these substances reveals the numerous benefits they possess. For instance, research has found that psilocybin may be used in the treatment of anxiety while MDMA could be used to...

In a notice that was recently published in the Federal Register, the Drug Enforcement Agency (“DEA”) revised upwards its 2022 quota for the production of illicit controlled substances , such as DMT, MDMA and psilocybin, for research purposes. The agency adjusted its quota on...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into an agreement with an investor to complete a non-brokered private placeme...

DENVER, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, tod...

2021 marked Mydecine’s patent application for its MYCO-003 drug candidate It also marked notable clinical trials on various aspects, including smoking cessation Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for ther...

Psychedelic substances have been used for centuries among the pre-Columbian Aztec and Mayan societies as well as indigenous peoples of the Americas, which include the Huichol and the Mazatec. The use of smaller doses of psychedelics in societies such as the Mazatec people to support the he...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. ...